{"id":"b-arm-dac","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression / neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This triplet combination uses daunorubicin as a topoisomerase II inhibitor and intercalating agent, cytarabine as a nucleoside analog that disrupts DNA synthesis, and cladribine as a purine analog that accumulates in leukemic cells. Together, these agents work synergistically to kill rapidly dividing leukemic blasts through multiple mechanisms of DNA damage and cell cycle arrest.","oneSentence":"DAC (daunorubicin, cytarabine, and cladribine) is a combination chemotherapy regimen that damages leukemic cell DNA and inhibits nucleotide synthesis to induce apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:30.389Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) in adult patients"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07153497","phase":"PHASE2","title":"Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":132},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT07177079","phase":"PHASE1","title":"High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"Kittika Poonsombudlert","startDate":"2026-05-31","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT07389239","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06-23","conditions":"Ovarian Cancer, Advanced Malignant Solid Tumor","enrollment":24},{"nctId":"NCT05010772","phase":"PHASE1","title":"Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-25","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT06803693","phase":"PHASE2","title":"Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":152},{"nctId":"NCT04774393","phase":"PHASE1, PHASE2","title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-24","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":84},{"nctId":"NCT04093570","phase":"PHASE2","title":"A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)","status":"ENROLLING_BY_INVITATION","sponsor":"Taiho Oncology, Inc.","startDate":"2019-09-30","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes","enrollment":332},{"nctId":"NCT02890329","phase":"PHASE1","title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-05","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related","enrollment":54},{"nctId":"NCT03240211","phase":"PHASE1","title":"Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2022-02-02","conditions":"PTCL, CTCL","enrollment":37},{"nctId":"NCT05766514","phase":"PHASE2","title":"Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2025-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT03092674","phase":"PHASE2, PHASE3","title":"Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-02","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia","enrollment":76},{"nctId":"NCT04623944","phase":"PHASE1","title":"NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nkarta, Inc.","startDate":"2020-09-21","conditions":"Relapsed/Refractory AML, AML, Adult, MDS","enrollment":61},{"nctId":"NCT04097470","phase":"PHASE2","title":"Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2019-12-05","conditions":"AML/MDS","enrollment":140},{"nctId":"NCT06441097","phase":"PHASE2","title":"Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":152},{"nctId":"NCT04113616","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-09-25","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)","enrollment":70},{"nctId":"NCT01812252","phase":"PHASE2","title":"Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-08-19","conditions":"Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":50},{"nctId":"NCT05907499","phase":"PHASE3","title":"Decitabine for Poor Graft Function Post Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-07-01","conditions":"Poor Graft Function","enrollment":76},{"nctId":"NCT05669079","phase":"PHASE3","title":"Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-08-01","conditions":"Poor Graft Function","enrollment":100},{"nctId":"NCT02878785","phase":"PHASE1, PHASE2","title":"Decitabine and Talazoparib in Untreated AML and R/R AML","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT05351346","phase":"PHASE3","title":"Genotype-guided Treatment in DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-06-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":1100},{"nctId":"NCT01420926","phase":"PHASE2","title":"Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Therapy-Related Acute Myeloid Leukemia","enrollment":165},{"nctId":"NCT02109744","phase":"PHASE1, PHASE2","title":"Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2014-03","conditions":"Acute Myelogenous Leukemia","enrollment":27},{"nctId":"NCT01177540","phase":"PHASE2","title":"Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2011-03-03","conditions":"Pediatric Acute Myelogenous Leukemia (AML)","enrollment":25},{"nctId":"NCT03217838","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2017-07-31","conditions":"Acute Myeloid Leukaemia","enrollment":50},{"nctId":"NCT02214407","phase":"PHASE3","title":"Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2014-10-14","conditions":"MDS","enrollment":170},{"nctId":"NCT03257241","phase":"PHASE3","title":"A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old","status":"UNKNOWN","sponsor":"Polish Adult Leukemia Group","startDate":"2017-07-03","conditions":"Acute Myeloid Leukemia","enrollment":582},{"nctId":"NCT01546038","phase":"PHASE2","title":"A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06-27","conditions":"Acute Myeloid Leukemia","enrollment":255},{"nctId":"NCT02272478","phase":"PHASE2, PHASE3","title":"Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations","status":"UNKNOWN","sponsor":"Cardiff University","startDate":"2014-10-30","conditions":"Acute Myeloid Leukaemia, Myelodysplastic Syndrome","enrollment":1600},{"nctId":"NCT02472145","phase":"PHASE2, PHASE3","title":"An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-04","conditions":"Leukemia, Myeloid, Acute","enrollment":326},{"nctId":"NCT03579082","phase":"PHASE4","title":"A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2018-06-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT03558412","phase":"PHASE4","title":"A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2018-06-01","conditions":"T-lymphoblastic Lymphoma","enrollment":40},{"nctId":"NCT02532010","phase":"PHASE2","title":"Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2015-06-15","conditions":"Acute Myeloid Leukemia (AML)","enrollment":13},{"nctId":"NCT01282476","phase":"PHASE2","title":"Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2011-06","conditions":"Diffuse Large B Cell Lymphoma","enrollment":18},{"nctId":"NCT01628471","phase":"PHASE1, PHASE2","title":"MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Uman Pharma","startDate":"2012-11","conditions":"Non Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT00943553","phase":"PHASE2","title":"A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects","status":"WITHDRAWN","sponsor":"Eisai Inc.","startDate":"2010-06","conditions":"Acute Myelogenous Leukemia (AML)","enrollment":""},{"nctId":"NCT00075634","phase":"PHASE1","title":"Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-12","conditions":"Recurrent Neuroblastoma, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":21},{"nctId":"NCT00538876","phase":"PHASE1","title":"Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-07","conditions":"Acute Myeloid Leukemia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Daunorubicin, Cladribine, Cytarabine"],"phase":"phase_3","status":"active","brandName":"B arm (DAC)","genericName":"B arm (DAC)","companyName":"Polish Adult Leukemia Group","companyId":"polish-adult-leukemia-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAC (daunorubicin, cytarabine, and cladribine) is a combination chemotherapy regimen that damages leukemic cell DNA and inhibits nucleotide synthesis to induce apoptosis. Used for Acute myeloid leukemia (AML) in adult patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}